



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 5, 2009

To: Primary Clinical Research Associates

From: Sara M. Braun
Protocol Development Coordinator

Re: N0877, Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Please note that this study was approved by the National Cancer Institute on May 8, 2009.

If you have any questions, please feel free to contact me.

Enclosure